Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose colchicine in high-risk coronary artery disease with residual inflammation
ISRCTN46375134Phase 4Completed
- Sponsor
- King's College Hospital
- Start
- Jun 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 4, randomised, open-label trial of colchicine in coronary arteriosclerosis, atherosclerosis, Chronic Coronary Syndrome (CCS) and 1 more (2 arms), sponsored by King's College Hospital. Primary endpoint: Minimal fibrous cap thickness. Started Jun 2024; status: completed.
02
Drugs
colchicine
03
Conditions
coronary arteriosclerosisatherosclerosisChronic Coronary Syndrome (CCS)chronic inflammation
Beyond the preview
Go deeper on ISRCTN46375134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN46375134.